Department of Hospital-Acquired Infection Control, Peking University People's Hospital, Beijing, The People's Republic of China.
Department of Hospital-Acquired Infection Control, Beijing Jishuitan Hospital, Beijing, The People's Republic of China.
PLoS One. 2020 Nov 9;15(11):e0241947. doi: 10.1371/journal.pone.0241947. eCollection 2020.
A recent cluster of pneumonia cases in Wuhan, China, has been caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We propose the protocol described below to perform an individual-patient data (IPD) network meta-analysis (NMA) in order to evaluate the efficacies of different antiviral drugs to treat patients with coronavirus disease 2019 (COVID-19).
We will search the Medline, EMBASE, Cochrane Library, SinoMed, CNKI and VIP databases from their inceptions through July 2020. There will be no restrictions on language, publication year, or publication type. Randomized clinical trials (RCTs) and prospective cohort studies with antiviral treatments for COVID-19 will be considered. Two reviewers will independently select studies and collect data. Risk-of-bias assessments will be completed using the Cochrane risk-of-bias scale. Primary outcome will be the COVID-19 recovery rate. We will combine aggregated data from IPD with the NMA in a single model, compare the effects of different antiviral drugs on patient-relevant efficacy, and rank the results to decide which is the most effective.
PROSPERO registration number: CRD42020167038.
近期在中国武汉发生了一组肺炎病例，其病因是严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）。我们提出了如下方案，以便开展个体化患者数据（IPD）网络荟萃分析（NMA），从而评估不同抗病毒药物治疗 2019 冠状病毒病（COVID-19）患者的疗效。
我们将从各数据库建库起至 2020 年 7 月检索 Medline、EMBASE、Cochrane 图书馆、中国生物医学文献数据库（SinoMed）、中国知网（CNKI）和维普中文期刊服务平台（VIP）。检索语种、发表年份和文献类型均不受限制。我们将纳入使用抗病毒药物治疗 COVID-19 的随机对照试验（RCT）和前瞻性队列研究。两名评审员将独立筛选研究并提取数据。使用 Cochrane 偏倚风险评估工具评估偏倚风险。主要结局指标为 COVID-19 康复率。我们将在单一模型中合并 IPD 的汇总数据和 NMA，比较不同抗病毒药物对患者相关疗效的影响，并对结果进行排名，以确定哪种药物最有效。
PROSPERO 注册号：CRD42020167038。
